The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase.

Abstract

Vasoactive intestinal peptide (VIP) stimulates the neuroblastoma cell line (NMB) to proliferate. Neuropeptide activity can be inhibited by neutral endopeptidases that function intracellularly and in the extracellular milieu. NMB cells express neutral endopeptidase (NEP) activity that can be specifically inhibited by phosphoramidon (PA). Our data now show that phosphoramidon treatment increases the efficacy of VIP-stimulated neuroblastoma proliferation. These results suggest that membrane endopeptidases modulate VIP-associated cell proliferation and enhancement of endopeptidase activity may serve as a target for cancer therapy.

• Authors: Yoram Wollman, Shmariahu Blumberg, Anya Spungin, Douglas E Brenneman, Mati Fridkin, Jonathan Wollman, Adrian Iaina, Illana Gozes
• Journal: Regulatory peptides (Regul Pept) Vol. 108 Issue 2-3 Pg. 175-7 (Oct 15 2002) ISSN: 0167-0115 [Print] Netherlands
• PMID: 12220742 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Enzyme Inhibitors
• Glycopeptides
• Vasoactive Intestinal Peptide
• Neprilysin
• phosphoramidon

Topics

• Cell Division (drug effects)
• Enzyme Inhibitors (pharmacology)
• Glycopeptides (pharmacology)
• Humans
• Neprilysin (metabolism)
• Neuroblastoma (pathology)
• Tumor Cells, Cultured
• Vasoactive Intestinal Peptide (pharmacology)